| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5912247 | Multiple Sclerosis and Related Disorders | 2014 | 11 Pages |
Abstract
The safety profile of fingolimod has been well characterized in this large combined trial population. Although infrequent SAEs can occur, there is no increased risk of infections, malignancies or serious cardiovascular events versus placebo.
Keywords
LRTIfreedomsSphingosine 1-phosphate receptorPRESULNFingolimodS1PRHPSPMLSafetyPooled analysisTRANSFORMSUpper limit of normalAtrioventricularCardiovascular eventsPosterior reversible encephalopathy syndromeHaemophagocytic syndromeLower respiratory tract infectionAdverse eventsProgressive multifocal leukoencephalopathyMultiple sclerosis
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Ludwig Kappos, Jeffrey Cohen, William Collins, Ana de Vera, Lixin Zhang-Auberson, Shannon Ritter, Philipp von Rosenstiel, Gordon Francis,